invention provides a crystalline form of canagliflozin or hydrate thereof designated as form c in one embodiment the crystalline form c is characterized by a powder x ray diffraction pattern comprising the following 2 u03b8 values measured using cuk u03b1 radiation 6 5 u00b0 u00b1 0 2 u00b0 9 8 u00b0 u00b1 0 2 u00b0 and 16 4 u00b0 u00b1 0 2 u00b0 in another embodiment the powder x ray diffraction pattern of crystalline form c further comprises the following 2 u03b8 values measured using cuk u03b1 radiation 13 1 u00b0 u00b1 0 2 u00b0 19 8 u00b0 u00b1 0 2 u00b0 and 23 7 u00b0 u00b1 0 2 u00b0 in another embodiment the powder x ray diffraction pattern of crystalline form c further comprises the following 2 u03b8 values measured using cuk u03b1 radiation 17 1 u00b0 u00b1 0 2 u00b0 19 5 u00b0 u00b1 0 2 u00b0 25 2 u00b0 u00b1 0 2 u00b0 and 26 5 u00b0 u00b1 0 2 u00b0 in another embodiment the crystalline form c has an x ray diffraction pattern substantially as depicted in fig6 in another embodiment the crystalline form c has a differential scanning calorimetry thermogram comprising two endothermic peaks at about 42 9 u00b0 c and about 82 2 u00b0 c respectively as shown in fig7 in another embodiment the crystalline form c of canagliflozin has a thermal gravimetric analysis tga thermogram comprising about 3 86 weight loss up to 130 u00b0 c as shown in fig8 while not intended to be limiting based on the tga data the form c appears to be or is close to be a monohydrate form 1 0 molecule h.